SlideShare uma empresa Scribd logo
1 de 12
Baixar para ler offline
Lifecycle Management Excellence:
                                    High-Performing Strategies
                            Used to Maximize Potential Of Mature Brands




                              Best Practices, LLC Strategic Benchmarking Research



Copyright © Best Practices®, LLC
                                                                                    BEST PRACTICES,   ®
                                                                                                          LLC
Table of Contents
                          Executive Summary,                                 pp. 3-11
                                Research Overview,                           pp. 4
                                Benchmark Participants,                      pp. 5
                                Key Findings & Insights,                     pp. 6-11
                          Corporate LCM Goals & Policies,                    pp. 12-15
                          Use of Key LCM Strategies,                         pp. 16-19
                          Comparative Effectiveness of Key LCM Strategies,   pp. 20-22
                          Relative Costs of Key LCM Strategies,              pp. 23-25
                          Relative Time of Key LCM Strategies,               pp. 26-28
                          ROI of Key LCM Strategies,                         pp. 29-31
                          Barriers of Key LCM Strategies,                    pp. 32-35
                          Key Strategy Profiles,                             pp. 36-39
                          Gains from Using LCM Strategies,                   pp. 40-46
                          Strategies Weakened By Regulation or Reform,       pp. 47-48
                          Mature Brand Organizations,                        pp. 49-61
                          Success Factors & Lessons Learned,                 pp. 62-66
                          Case Example: Pfizer’s Lipitor,                    pp. 67-70
                          Appendix: Participant Demographic Data,            pp. 71-75




Copyright © Best Practices®, LLC                          2
                                                                                BEST PRACTICES,   ®
                                                                                                      LLC
Research Project Objective & Methodology
   Best Practices, LLC conducted this benchmarking study to examine the relative effectiveness of
   20+ strategies for extending the commercial life of mature pharmaceutical products. The study also
   compares the goals and responsibilities of Mature Brand (MB) organizations.

      Business Issue:
        With expiring patents & thin pipelines, pharmaceutical companies are increasingly focused
        on lifecycle management (LCM) planning to make the most of each brand at every stage of
        its life, including the somewhat neglected back end. In this context, executives seek to
        understand what strategies and corporate structures are most effective for extending the
        commercial life of its mature products.

       Key Areas of Investigation:                         Field Research :           Result:

     1. Success rates & ROI of different                    Deployed online           Provide
        strategies that leading companies have              survey to                 marketing &
        used to maximize mature-brand value                 representative            brand leaders
                                                            group of pharma           with directional
     2. Relative cost, time, complexity, &                  brand &                   data & proven
        regulatory barriers encountered with
                                                            marketing                 practices they
        using each strategy
                                                            leaders with              can use to gain
     3. An overview of the operation, expenses,             experience in             maximum value
        responsibilities & business impact of               LCM.                      from late-life
        dedicated mature brand (MB) groups                                            products
                                                            Sample Size: 25

Copyright © Best Practices®, LLC                      3
                                                                                    BEST PRACTICES,      ®
                                                                                                             LLC
Universe of Learning: Benchmark Participants
  Research participants included 25 executives and managers from 18 different pharmaceutical and
  biotech companies. Respondents represented more than a dozen therapeutic areas. On average, this
  seasoned group boasts U.S. leadership experience with eight mature products. Two-thirds of this group
  currently work at the director level or above.

                                        Benchmark Class:




Copyright © Best Practices®, LLC                    4
                                                                                  BEST PRACTICES,   ®
                                                                                                        LLC
Key Findings: Selected Benchmark Metrics
    The following key findings emerged from this study.




         Litigation Has Highest ROI: Overall, litigation strategies achieved the highest ROI for
         participants, with 40% realizing more than 100% ROI and another 20% realizing over 50%.
         Fixed dose combination, one of the more expensive strategies, had the second highest ROI
         rating. With respect to time and costs, branded/authorized generics was the most effective
         strategy in garnering a high ROI.

         Most Used LCM Strategies: Almost two-thirds of participants use strategic pricing or
         publication strategies as a lifecycle management tactic.

         Efficiency: Strategic pricing is rated by the benchmark class as the most cost- and
         time-efficient strategy.

         Time Used: On average, benchmark partners used each LCM strategy for 21 months in
         support of mature brands, with a maximum time of 96 months for a strategy.

         Financial Gain: Financial gain from using individual strategies among the benchmark class
         ranged from $0 to $10 billion, with a median gain of $30 million. The average gain was $254
         million.

Copyright © Best Practices®, LLC                       5
                                                                                       BEST PRACTICES,   ®
                                                                                                             LLC
Benchmarked LCM Strategies for Use with Mature Brands
  This study benchmarked the use of 19 development, new formulation, commercial, and legal
  strategies used to extend the commercial life of mature, legacy pharmaceutical brands.


                                        •   Added safety features
      Development & New                 •   Extended release formulation
     Formulation Strategies             •   Fixed dose combination
                                        •   New dosage form (e.g., patch)
                                        •   New dosing regimen
             Aimed at
              Aimed at                  •   New Indication
             enlarging
              enlarging                 •   Shelf-stable version
            patient base
             patient base
                                        •   Add-on services (e.g., reimbursement assistance)
                                        •   Brand loyalty programs
      Commercial & Legal/               •   Branded/authorized generics
      Regulatory Strategies             •   Contracting with large-volume purchasers
                                        •   Extending into new, emerging markets (e.g., China)
              Aimed at                  •   Labeling changes
               Aimed at                 •   Litigation
             maximizing
              maximizing                •   OTC switching
             commercial
              commercial                •   Packaging innovations (e.g., co-packaging 2 drugs)
               value &
                value &                 •   Publication strategy demonstrating clinical superiority
              extending
               extending                •   Repositioning product
            protected life
             protected life             •   Strategic pricing

Copyright © Best Practices®, LLC                    6
                                                                                   BEST PRACTICES,    ®
                                                                                                          LLC
LCM Strategies Are Widely Used by Benchmark Participants
 More than two-thirds of benchmark participants have experience with the top four LCM strategies
 examined in this study. New dosage form is the most-used strategy overall (75%). More than half of
 companies have experience with extending into emerging markets.

           Q. Please indicate which of the following strategies you have used in the U.S. during your
                                         career. (Check all that apply.)
                                                     LCM Strategy Usage
                                        New dosage form (e.g., patch, liquid)                                               75%
                        Publication strategy demonstrating superior clinical
                                                                                                                      67%
                              attributes (safety, efficacy, convenience)
                                                        New dosing regimen                                            67%

                                                              New indication                                          67%
                       Strategic pricing (adjusting price to maintain sales or
                                                                                                                     63%
                                              growth)
                                               Branded/authorized generics                                      58%

                         Extending into new, emerging markets (e.g., China)                                    54%

                                                      Repositioning product                                    54%

                                                      Brand loyalty programs                                   54%
                                       Add-on services (e.g., reimbursement
                                                                                                              50%
                                            assistance/patient support)
                                   Contracting with large-volume purchasers                                   50%
                                                                                 % Responses
 (n=24)                        * Other: Taste enhancements, Reduce complexity, Contract Sales Organizations

Copyright © Best Practices®, LLC                                  7
                                                                                                       BEST PRACTICES,        ®
                                                                                                                                  LLC
All Strategies Used by at Least 25% of Participants; Other by 21%
 * Benchmark partners listed eight additional strategies, indicated in the “Other” bars below.
   Other Commercial strategies include: Building alternative promotional channels, CSOs, reducing
   complexity, post-patent contracting, and taste enhancements. Other Development strategies include:
   drug/device combination and packaging.
            Q. Please indicate which of the following strategies you have used in the U.S. during your
                                          career. (Check all that apply.)
                                           LCM Strategy Usage, Continued
                 Packaging innovations (e.g., co-packaging
                                                                                                50%
                         complementary drugs)
                             Extended release formulation                                       50%
                                                Labeling changes                              46%
 Added safety features (e.g., abuse resistant product)                                    38%
        Fixed dose combination (e.g., combining two
                                                                                          38%
                  complimentary products)
                                  Litigation strategies                             29%
                                                                                              Benchmark
                                                   OTC switching                   25%        participants
                                   * Other commercial strategies                  21%            used an
              Shelf-stable version (e.g., no longer requires                                average of four
                                                                             17%
    Other




                               refrigeration)                                                different LCM
                                                                        8%                   strategies for
                            * Other development strategies
                                       *
                                                                                            mature brands.
                                           Other new formulations    4%
 (n=24)                                                             % Responses

Copyright © Best Practices®, LLC                           8
                                                                                         BEST PRACTICES,      ®
                                                                                                                  LLC
Strategy Profiles: Overview of Mature Brand LCM Tactics
 The next three slides summarize findings regarding the most commonly used strategies in this study.
 NOTE: Green arrows indicate New Formulations strategies; Light blue = Commercial strategies; Dark
 blue = Development strategies. Values in red type represent the % of respondents rating each strategy
 “Highly Effective.” Only barriers with a response greater than 50% are shown.
          Strategy:                            Overview:                           Considerations:
                                   •   75% used                        •    Average ROI: 58%
     New Dosage Form               •   88% users rated Effective (38%) •    Barrier(s): Technical Feasibility (57%)
     (e.g., patch, liquid)         •   Time: 76% Rated > 3 years       •    Weakened by Regulation: High
                                   •   Cost: 44% Rated > $10 million
                                   •   67% used                         •   Average ROI: 64%
  Publication strategy
                                   •   86% users rated Effective (7%)   •   Barrier(s): Length of Time (57%)
 demonstrating superior
                                   •   Time: 80% Rated < 2 years        •   Weakened by Regulation: High
    clinical attribute
                                   •   Cost: 54% Rated $1-5 Million
                                   •   67% used                        •    Average ROI: 51%
    New Dosing Regimen             •   71% users rated Effective (14%) •    Barrier(s): Length of Time (61%),
                                   •   Time: 77% Rated > 3 years            Regulatory Feasibility (57%)
                                   •   Cost: 42% Rated $1-5 Million    •    Weakened by Regulation: Medium
                                   •   67% used                        •    Average ROI: 69%
                                   •   86% users rated Effective (40%) •    Barrier(s): High Cost (83%), Length of
        New Indication
                                   •   Time: 80% Rated > 3 years            Time (74%), Reg. Feasibility (70%)
                                   •   Cost: 57% Rated > $10 million   •    Weakened by Regulation: Medium
                                   •   63% used                        •    Average ROI: 34%
                                   •   72% users rated Effective (29%) •    Barrier(s): None
      Strategic Pricing
                                   •   Time: 93% Rated < 1 year        •    Weakened by Regulation: High
                                   •   Cost: 66% Rated < $1 million
Copyright © Best Practices®, LLC                            9
                                                                                              BEST PRACTICES,     ®
                                                                                                                      LLC
Regulation & Reform Are Weakening Current Strategies
  More than a quarter of benchmark partners expect strategies used successfully in the past to be less
  effective in the future, due to regulatory issues in the current healthcare environment. Publication
  strategies and brand loyalty programs are viewed as the most vulnerable. Other strategies that will be
  affected include new dosage form, branded/authorized generics, and strategic pricing.
   Q. Given the current health care reform environment, politics, mature drug shortages and other regulatory issues, do
  you expect any strategies that you have used successfully in the past to become ineffective or unusable within the next
                                           12-24 months? (Check all that apply.)
                                       Strategies Weakened by Regulation/Reform:
   Publication strategy demonstrating superior clinical
                                                                               28%
         attributes (safety, efficacy, convenience)                                    Other Strategies Selected
                                                                                       Other Strategies Selected
                                                                                             More Than Once:
                                                                                             More Than Once:
                                        Brand loyalty programs                 28%   • Add-on services (e.g.,
                                                                                     • Add-on services (e.g.,
                                                                                       reimbursement assistance/
                                                                                       reimbursement assistance/
                                                                                       patient support)
                                                                                       patient support)
     Strategic pricing (adjusting price to maintain sales
                                                                          22%
                          or growth)                                                 • Extended release
                                                                                     • Extended release
                                                                                       formulation
                                                                                        formulation
                                   Branded/authorized generics            22%
                                                                                     • New indication
                                                                                     • New indication
                                                                                     • New dosing regimen
                                                                                     • New dosing regimen
                       New dosage form (e.g., patch, liquid)              22%
                                                                                     • Repositioning product
                                                                                     • Repositioning product
            Fixed dose combination (e.g., combining two                              • Packaging innovations (e.g.,
                                                                                     • Packaging innovations (e.g.,
                                                                       17%
                     complimentary products)                                           co-packaging
                                                                                       co-packaging
                                                                                       complementary drugs)
                                                                                       complementary drugs)
                                                                 % Responses
 (n=18)
Copyright © Best Practices®, LLC                                 10
                                                                                                 BEST PRACTICES,      ®
                                                                                                                          LLC
More Than Half Have a Dedicated Mature Brands Organization
   Dedicated mature brand (MB) organizations are in place at 52% of the companies in this study.
   For those with no dedicated MB group, brand teams are most often responsible for maximizing
   the commercial success of mature products.

   Q. Does your company have a group or function dedicated to managing and supporting mature/legacy products in the
            U.S. market? (Choose one.) If no, who is responsible for maximizing mature products in the U.S.?

          Dedicated Function Managing                                        Responsible Party if No
         Mature Brands in the U.S. Market:                                       Dedicated MB:

                                                                                        Mature Products
                                                                                       Commercial Team
                                                                          Brand               9%
                                                                      Lead/Marketing
                                                                         Director
                                                                            9%
               Yes                  No                                 Global
               52%                 48%                                Marketing
                                                                         9%                Brand Teams
                                                                                               73%




 (n=25)                                                                 (n = 11)
Copyright © Best Practices®, LLC                          11
                                                                                             BEST PRACTICES,     ®
                                                                                                                      LLC
About Best Practices, LLC
  Best Practices, LLC is a research and consulting firm that conducts work based on the simple yet
  profound principle that organizations can chart a course to superior economic performance by studying
  the best business practices, operating tactics, and winning strategies of world-class companies.




                                   Best Practices, LLC
                                    6350 Quadrangle Drive, Suite 200,
                                          Chapel Hill, NC 27517
                                         www.best-in-class.com
                                        Telephone: 919-403-0251
                                        best@best-in-class.com




Copyright © Best Practices®, LLC                    12
                                                                                  BEST PRACTICES,   ®
                                                                                                        LLC

Mais conteúdo relacionado

Mais de Marty Daniel with ThunderActive

SM 169A High-Performance Market Research Functions Report Summary
SM 169A High-Performance Market Research Functions Report SummarySM 169A High-Performance Market Research Functions Report Summary
SM 169A High-Performance Market Research Functions Report Summary
Marty Daniel with ThunderActive
 

Mais de Marty Daniel with ThunderActive (10)

Professional and Trade Relations Excellence Report Summary
Professional and Trade Relations Excellence Report SummaryProfessional and Trade Relations Excellence Report Summary
Professional and Trade Relations Excellence Report Summary
 
Government Affairs and Public Policy Excellence Report Summary
Government Affairs and Public Policy Excellence Report SummaryGovernment Affairs and Public Policy Excellence Report Summary
Government Affairs and Public Policy Excellence Report Summary
 
Corporate Affairs Excellence Report Summary
Corporate Affairs Excellence Report SummaryCorporate Affairs Excellence Report Summary
Corporate Affairs Excellence Report Summary
 
Pharma New Product Planning- Medical Affairs Report Summary
Pharma New Product Planning- Medical Affairs Report SummaryPharma New Product Planning- Medical Affairs Report Summary
Pharma New Product Planning- Medical Affairs Report Summary
 
Pharma Public Affairs- Resources Required to Serve the US Market Report Summary
Pharma Public Affairs- Resources Required to Serve the US Market Report SummaryPharma Public Affairs- Resources Required to Serve the US Market Report Summary
Pharma Public Affairs- Resources Required to Serve the US Market Report Summary
 
SM 169A High-Performance Market Research Functions Report Summary
SM 169A High-Performance Market Research Functions Report SummarySM 169A High-Performance Market Research Functions Report Summary
SM 169A High-Performance Market Research Functions Report Summary
 
New Product Launch Spend Report Summary
New Product Launch Spend Report SummaryNew Product Launch Spend Report Summary
New Product Launch Spend Report Summary
 
Health Outcomes Report Summary
Health Outcomes Report SummaryHealth Outcomes Report Summary
Health Outcomes Report Summary
 
Optimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report SummaryOptimizing KOL Relationships Report Summary
Optimizing KOL Relationships Report Summary
 
OP 106A Raising Disease State Awareness Report Summary
OP 106A Raising Disease State Awareness Report SummaryOP 106A Raising Disease State Awareness Report Summary
OP 106A Raising Disease State Awareness Report Summary
 

Último

Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...
Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...
Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...
lizamodels9
 
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Anamikakaur10
 
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
daisycvs
 
Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...
Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...
Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...
amitlee9823
 
Insurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usageInsurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usage
Matteo Carbone
 
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
amitlee9823
 
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabiunwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
Abortion pills in Kuwait Cytotec pills in Kuwait
 

Último (20)

Eluru Call Girls Service ☎ ️93326-06886 ❤️‍🔥 Enjoy 24/7 Escort Service
Eluru Call Girls Service ☎ ️93326-06886 ❤️‍🔥 Enjoy 24/7 Escort ServiceEluru Call Girls Service ☎ ️93326-06886 ❤️‍🔥 Enjoy 24/7 Escort Service
Eluru Call Girls Service ☎ ️93326-06886 ❤️‍🔥 Enjoy 24/7 Escort Service
 
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
The Path to Product Excellence: Avoiding Common Pitfalls and Enhancing Commun...
 
Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1Katrina Personal Brand Project and portfolio 1
Katrina Personal Brand Project and portfolio 1
 
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
Enhancing and Restoring Safety & Quality Cultures - Dave Litwiller - May 2024...
 
Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...
Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...
Call Girls In DLf Gurgaon ➥99902@11544 ( Best price)100% Genuine Escort In 24...
 
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
Call Now ☎️🔝 9332606886🔝 Call Girls ❤ Service In Bhilwara Female Escorts Serv...
 
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
Quick Doctor In Kuwait +2773`7758`557 Kuwait Doha Qatar Dubai Abu Dhabi Sharj...
 
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdfDr. Admir Softic_ presentation_Green Club_ENG.pdf
Dr. Admir Softic_ presentation_Green Club_ENG.pdf
 
Cracking the Cultural Competence Code.pptx
Cracking the Cultural Competence Code.pptxCracking the Cultural Competence Code.pptx
Cracking the Cultural Competence Code.pptx
 
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best ServicesMysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
Mysore Call Girls 8617370543 WhatsApp Number 24x7 Best Services
 
Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...
Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...
Call Girls Jp Nagar Just Call 👗 7737669865 👗 Top Class Call Girl Service Bang...
 
Falcon's Invoice Discounting: Your Path to Prosperity
Falcon's Invoice Discounting: Your Path to ProsperityFalcon's Invoice Discounting: Your Path to Prosperity
Falcon's Invoice Discounting: Your Path to Prosperity
 
Insurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usageInsurers' journeys to build a mastery in the IoT usage
Insurers' journeys to build a mastery in the IoT usage
 
Falcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investorsFalcon Invoice Discounting: The best investment platform in india for investors
Falcon Invoice Discounting: The best investment platform in india for investors
 
Organizational Transformation Lead with Culture
Organizational Transformation Lead with CultureOrganizational Transformation Lead with Culture
Organizational Transformation Lead with Culture
 
A DAY IN THE LIFE OF A SALESMAN / WOMAN
A DAY IN THE LIFE OF A  SALESMAN / WOMANA DAY IN THE LIFE OF A  SALESMAN / WOMAN
A DAY IN THE LIFE OF A SALESMAN / WOMAN
 
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
Call Girls Electronic City Just Call 👗 7737669865 👗 Top Class Call Girl Servi...
 
Call Girls Zirakpur👧 Book Now📱7837612180 📞👉Call Girl Service In Zirakpur No A...
Call Girls Zirakpur👧 Book Now📱7837612180 📞👉Call Girl Service In Zirakpur No A...Call Girls Zirakpur👧 Book Now📱7837612180 📞👉Call Girl Service In Zirakpur No A...
Call Girls Zirakpur👧 Book Now📱7837612180 📞👉Call Girl Service In Zirakpur No A...
 
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabiunwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
unwanted pregnancy Kit [+918133066128] Abortion Pills IN Dubai UAE Abudhabi
 
Call Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine ServiceCall Girls In Panjim North Goa 9971646499 Genuine Service
Call Girls In Panjim North Goa 9971646499 Genuine Service
 

Lifecycle Management Excellence: High-Performing Strategies Used to Maximize Potential of Mature Brands Report Summary

  • 1. Lifecycle Management Excellence: High-Performing Strategies Used to Maximize Potential Of Mature Brands Best Practices, LLC Strategic Benchmarking Research Copyright © Best Practices®, LLC BEST PRACTICES, ® LLC
  • 2. Table of Contents Executive Summary, pp. 3-11 Research Overview, pp. 4 Benchmark Participants, pp. 5 Key Findings & Insights, pp. 6-11 Corporate LCM Goals & Policies, pp. 12-15 Use of Key LCM Strategies, pp. 16-19 Comparative Effectiveness of Key LCM Strategies, pp. 20-22 Relative Costs of Key LCM Strategies, pp. 23-25 Relative Time of Key LCM Strategies, pp. 26-28 ROI of Key LCM Strategies, pp. 29-31 Barriers of Key LCM Strategies, pp. 32-35 Key Strategy Profiles, pp. 36-39 Gains from Using LCM Strategies, pp. 40-46 Strategies Weakened By Regulation or Reform, pp. 47-48 Mature Brand Organizations, pp. 49-61 Success Factors & Lessons Learned, pp. 62-66 Case Example: Pfizer’s Lipitor, pp. 67-70 Appendix: Participant Demographic Data, pp. 71-75 Copyright © Best Practices®, LLC 2 BEST PRACTICES, ® LLC
  • 3. Research Project Objective & Methodology Best Practices, LLC conducted this benchmarking study to examine the relative effectiveness of 20+ strategies for extending the commercial life of mature pharmaceutical products. The study also compares the goals and responsibilities of Mature Brand (MB) organizations. Business Issue: With expiring patents & thin pipelines, pharmaceutical companies are increasingly focused on lifecycle management (LCM) planning to make the most of each brand at every stage of its life, including the somewhat neglected back end. In this context, executives seek to understand what strategies and corporate structures are most effective for extending the commercial life of its mature products. Key Areas of Investigation: Field Research : Result: 1. Success rates & ROI of different Deployed online Provide strategies that leading companies have survey to marketing & used to maximize mature-brand value representative brand leaders group of pharma with directional 2. Relative cost, time, complexity, & brand & data & proven regulatory barriers encountered with marketing practices they using each strategy leaders with can use to gain 3. An overview of the operation, expenses, experience in maximum value responsibilities & business impact of LCM. from late-life dedicated mature brand (MB) groups products Sample Size: 25 Copyright © Best Practices®, LLC 3 BEST PRACTICES, ® LLC
  • 4. Universe of Learning: Benchmark Participants Research participants included 25 executives and managers from 18 different pharmaceutical and biotech companies. Respondents represented more than a dozen therapeutic areas. On average, this seasoned group boasts U.S. leadership experience with eight mature products. Two-thirds of this group currently work at the director level or above. Benchmark Class: Copyright © Best Practices®, LLC 4 BEST PRACTICES, ® LLC
  • 5. Key Findings: Selected Benchmark Metrics The following key findings emerged from this study. Litigation Has Highest ROI: Overall, litigation strategies achieved the highest ROI for participants, with 40% realizing more than 100% ROI and another 20% realizing over 50%. Fixed dose combination, one of the more expensive strategies, had the second highest ROI rating. With respect to time and costs, branded/authorized generics was the most effective strategy in garnering a high ROI. Most Used LCM Strategies: Almost two-thirds of participants use strategic pricing or publication strategies as a lifecycle management tactic. Efficiency: Strategic pricing is rated by the benchmark class as the most cost- and time-efficient strategy. Time Used: On average, benchmark partners used each LCM strategy for 21 months in support of mature brands, with a maximum time of 96 months for a strategy. Financial Gain: Financial gain from using individual strategies among the benchmark class ranged from $0 to $10 billion, with a median gain of $30 million. The average gain was $254 million. Copyright © Best Practices®, LLC 5 BEST PRACTICES, ® LLC
  • 6. Benchmarked LCM Strategies for Use with Mature Brands This study benchmarked the use of 19 development, new formulation, commercial, and legal strategies used to extend the commercial life of mature, legacy pharmaceutical brands. • Added safety features Development & New • Extended release formulation Formulation Strategies • Fixed dose combination • New dosage form (e.g., patch) • New dosing regimen Aimed at Aimed at • New Indication enlarging enlarging • Shelf-stable version patient base patient base • Add-on services (e.g., reimbursement assistance) • Brand loyalty programs Commercial & Legal/ • Branded/authorized generics Regulatory Strategies • Contracting with large-volume purchasers • Extending into new, emerging markets (e.g., China) Aimed at • Labeling changes Aimed at • Litigation maximizing maximizing • OTC switching commercial commercial • Packaging innovations (e.g., co-packaging 2 drugs) value & value & • Publication strategy demonstrating clinical superiority extending extending • Repositioning product protected life protected life • Strategic pricing Copyright © Best Practices®, LLC 6 BEST PRACTICES, ® LLC
  • 7. LCM Strategies Are Widely Used by Benchmark Participants More than two-thirds of benchmark participants have experience with the top four LCM strategies examined in this study. New dosage form is the most-used strategy overall (75%). More than half of companies have experience with extending into emerging markets. Q. Please indicate which of the following strategies you have used in the U.S. during your career. (Check all that apply.) LCM Strategy Usage New dosage form (e.g., patch, liquid) 75% Publication strategy demonstrating superior clinical 67% attributes (safety, efficacy, convenience) New dosing regimen 67% New indication 67% Strategic pricing (adjusting price to maintain sales or 63% growth) Branded/authorized generics 58% Extending into new, emerging markets (e.g., China) 54% Repositioning product 54% Brand loyalty programs 54% Add-on services (e.g., reimbursement 50% assistance/patient support) Contracting with large-volume purchasers 50% % Responses (n=24) * Other: Taste enhancements, Reduce complexity, Contract Sales Organizations Copyright © Best Practices®, LLC 7 BEST PRACTICES, ® LLC
  • 8. All Strategies Used by at Least 25% of Participants; Other by 21% * Benchmark partners listed eight additional strategies, indicated in the “Other” bars below. Other Commercial strategies include: Building alternative promotional channels, CSOs, reducing complexity, post-patent contracting, and taste enhancements. Other Development strategies include: drug/device combination and packaging. Q. Please indicate which of the following strategies you have used in the U.S. during your career. (Check all that apply.) LCM Strategy Usage, Continued Packaging innovations (e.g., co-packaging 50% complementary drugs) Extended release formulation 50% Labeling changes 46% Added safety features (e.g., abuse resistant product) 38% Fixed dose combination (e.g., combining two 38% complimentary products) Litigation strategies 29% Benchmark OTC switching 25% participants * Other commercial strategies 21% used an Shelf-stable version (e.g., no longer requires average of four 17% Other refrigeration) different LCM 8% strategies for * Other development strategies * mature brands. Other new formulations 4% (n=24) % Responses Copyright © Best Practices®, LLC 8 BEST PRACTICES, ® LLC
  • 9. Strategy Profiles: Overview of Mature Brand LCM Tactics The next three slides summarize findings regarding the most commonly used strategies in this study. NOTE: Green arrows indicate New Formulations strategies; Light blue = Commercial strategies; Dark blue = Development strategies. Values in red type represent the % of respondents rating each strategy “Highly Effective.” Only barriers with a response greater than 50% are shown. Strategy: Overview: Considerations: • 75% used • Average ROI: 58% New Dosage Form • 88% users rated Effective (38%) • Barrier(s): Technical Feasibility (57%) (e.g., patch, liquid) • Time: 76% Rated > 3 years • Weakened by Regulation: High • Cost: 44% Rated > $10 million • 67% used • Average ROI: 64% Publication strategy • 86% users rated Effective (7%) • Barrier(s): Length of Time (57%) demonstrating superior • Time: 80% Rated < 2 years • Weakened by Regulation: High clinical attribute • Cost: 54% Rated $1-5 Million • 67% used • Average ROI: 51% New Dosing Regimen • 71% users rated Effective (14%) • Barrier(s): Length of Time (61%), • Time: 77% Rated > 3 years Regulatory Feasibility (57%) • Cost: 42% Rated $1-5 Million • Weakened by Regulation: Medium • 67% used • Average ROI: 69% • 86% users rated Effective (40%) • Barrier(s): High Cost (83%), Length of New Indication • Time: 80% Rated > 3 years Time (74%), Reg. Feasibility (70%) • Cost: 57% Rated > $10 million • Weakened by Regulation: Medium • 63% used • Average ROI: 34% • 72% users rated Effective (29%) • Barrier(s): None Strategic Pricing • Time: 93% Rated < 1 year • Weakened by Regulation: High • Cost: 66% Rated < $1 million Copyright © Best Practices®, LLC 9 BEST PRACTICES, ® LLC
  • 10. Regulation & Reform Are Weakening Current Strategies More than a quarter of benchmark partners expect strategies used successfully in the past to be less effective in the future, due to regulatory issues in the current healthcare environment. Publication strategies and brand loyalty programs are viewed as the most vulnerable. Other strategies that will be affected include new dosage form, branded/authorized generics, and strategic pricing. Q. Given the current health care reform environment, politics, mature drug shortages and other regulatory issues, do you expect any strategies that you have used successfully in the past to become ineffective or unusable within the next 12-24 months? (Check all that apply.) Strategies Weakened by Regulation/Reform: Publication strategy demonstrating superior clinical 28% attributes (safety, efficacy, convenience) Other Strategies Selected Other Strategies Selected More Than Once: More Than Once: Brand loyalty programs 28% • Add-on services (e.g., • Add-on services (e.g., reimbursement assistance/ reimbursement assistance/ patient support) patient support) Strategic pricing (adjusting price to maintain sales 22% or growth) • Extended release • Extended release formulation formulation Branded/authorized generics 22% • New indication • New indication • New dosing regimen • New dosing regimen New dosage form (e.g., patch, liquid) 22% • Repositioning product • Repositioning product Fixed dose combination (e.g., combining two • Packaging innovations (e.g., • Packaging innovations (e.g., 17% complimentary products) co-packaging co-packaging complementary drugs) complementary drugs) % Responses (n=18) Copyright © Best Practices®, LLC 10 BEST PRACTICES, ® LLC
  • 11. More Than Half Have a Dedicated Mature Brands Organization Dedicated mature brand (MB) organizations are in place at 52% of the companies in this study. For those with no dedicated MB group, brand teams are most often responsible for maximizing the commercial success of mature products. Q. Does your company have a group or function dedicated to managing and supporting mature/legacy products in the U.S. market? (Choose one.) If no, who is responsible for maximizing mature products in the U.S.? Dedicated Function Managing Responsible Party if No Mature Brands in the U.S. Market: Dedicated MB: Mature Products Commercial Team Brand 9% Lead/Marketing Director 9% Yes No Global 52% 48% Marketing 9% Brand Teams 73% (n=25) (n = 11) Copyright © Best Practices®, LLC 11 BEST PRACTICES, ® LLC
  • 12. About Best Practices, LLC Best Practices, LLC is a research and consulting firm that conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics, and winning strategies of world-class companies. Best Practices, LLC 6350 Quadrangle Drive, Suite 200, Chapel Hill, NC 27517 www.best-in-class.com Telephone: 919-403-0251 best@best-in-class.com Copyright © Best Practices®, LLC 12 BEST PRACTICES, ® LLC